Defendant
1 case as defendant.
Alvogen, Inc. (also referenced as Alvogen Pharma US, Inc.; "Alvogen Pine Brook, LLC" appears in litigation filings) is a privately held, US-based pharmaceutical company headquartered in Morristown, New Jersey, with a manufacturing site in Norwich, New York. It was founded in 2009 by Róbert Wessman through the buyout of Norwich Pharmaceuticals. Wikipedia reports it has been majority-owned by CVC Capital Partners and Temasek Holdings since 2015. In September 2025 Alvogen announced an agreement to sell its parent company to Taiwan-listed Lotus Pharmaceutical Co., Ltd. (TWSE: 1795), and its own website now describes Alvogen as a wholly owned Lotus subsidiary. Size figures vary by source: the company states "more than 500 FTEs" in the US, while aggregators estimate roughly 2,400 employees and ~$700M revenue, and Wikipedia cites ~2,800 employees and $1.1B revenue (2017). These third-party figures are unverified.
Operations. Alvogen develops, in-licenses, manufactures, and markets pharmaceuticals through four businesses: Alvogen (generics), Almatica (branded products), Almaject (injectables), and Norwich (US manufacturing). Its stated pipeline focus is complex, high-value products — inhalation therapies, long-acting injectables, peptides, and strategic 505(b)(2) brands. The company reports 30–50-plus products on the market.
Litigation posture. Alvogen is an operating company, not a patent assertion entity. The case data show 1 tracked case, all as a defendant and none as plaintiff — consistent with an ANDA filer defending a Hatch-Waxman suit rather than asserting patents. The single tracked matter sits in the District of New Jersey, not a plaintiff-friendly venue such as the Eastern District of Texas.
Notable case. Celgene Corporation v. Lotus Pharmaceutical Co., Ltd. et al. (D.N.J., No. 2:17-cv-06842) arose from Lotus/Alvogen's ANDA No. 210480 for generic lenalidomide (branded Revlimid); Celgene asserted sixteen patents covering lenalidomide formulations, REMS methods, and polymorphs. The parties settled in March 2019, with a consent judgment and a volume-limited license permitting limited US sales from March 2022. At the time, Alvogen Group held a majority stake in co-defendant Lotus — the reverse of the 2025 ownership arrangement.
Celgene sued Lotus and Alvogen over ANDA No. 210480, asserting the '357, '219, and '598 patents. Markman hearings were canceled in 2019, and the docket reflects a judgment/injunction barring marketing. The case is the only '598 case indexed in the Stanford NPE Database and ended in consent judgment/injunction.